Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis.

Gut microbiome plays a role in immune response to mRNA COVID vaccines

Researchers from Karolinska Institutet in Sweden have discovered that the gut microbiome can influence how well people respond to mRNA COVID vaccines.

January 4, 2024

Exclusive: Lilly backs a16z-funded Arda Therapeutics’ $43M Series A to take ADCs into fibrosis

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 9, 2024

Opinion | An Evolutionary Perspective on Why the Lab Leak Theory Is Wrong

The House Select Subcommittee on the Coronavirus Pandemic published a “Hearing Wrap Up” in mid-July on the suppression of the lab leak hypothesis on COVID’s

August 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.